Literature DB >> 21691816

OATP 1B1/1B3 expression in hepatocellular carcinomas treated with orthotopic liver transplantation.

Francesco Vasuri1, Rita Golfieri, Michelangelo Fiorentino, Elisa Capizzi, Matteo Renzulli, Antonio D Pinna, Walter F Grigioni, Antonia D'Errico-Grigioni.   

Abstract

The organic anion transporter peptides (OATP) 1B1 and 1B3 are hepatocytic-specific transporters determinant for the uptake of the contrast media Gd-EOB-DTPA during magnetic resonance, but variably lost in hepatocellular carcinoma (HCC). Here, we studied a series of HCCs from livers that underwent liver transplantation (OLT) and correlated the expression of OATP 1B1/1B3 with HCC morphological features and the expression of the biliary-type keratins K7 and K19, the latter previously correlated with a worse prognosis after OLT. Seventy-five HCCs from 69 OLT patients were evaluated by histology and immunohistochemistry with monoclonal antibodies against OATP 1B1/1B3, K7, and K19. Histopathological and immunohistochemical features were therefore compared to recipient follow-up data. Thirty-four (45%) HCCs were completely OATP-, and 18 (24%) showed positivity for K7 and/or K19. We observed a significant inverse correlation between OATP and K7/19 expression (P < 0.001): all OATP+ cases were K7/19-, while all K7+ and/or K19+ cases were OATP-. Sixteen cases were negative for all antibodies. No correlation was found between histopathological features and immunohistochemistry. Twenty-five recipients experienced HCC recurrence, and ten died from neoplastic recurrence. Neither OATP nor keratin expressions were correlated with HCC recurrence, while OATP negativity significantly correlated with HCC-related death after recurrence (P = 0.036). In conclusion, HCCs show a progressive loss in OATP immunoreactivity that correlates with the gain of a biliary phenotype. Although further studies are required to define these findings better, our results support the idea that OATP could be used together with K7/19 to identify a phenotypical "spectrum" in HCC progression.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21691816     DOI: 10.1007/s00428-011-1099-5

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  28 in total

1.  Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies.

Authors:  H A EDMONDSON; P E STEINER
Journal:  Cancer       Date:  1954-05       Impact factor: 6.860

2.  Staging systems for predicting survival of patients with hepatocellular carcinoma after surgery.

Authors:  Lei-Bo Xu; Jie Wang; Chao Liu; Hao-Wei Pang; Ya-Jin Chen; Qing-Jia Ou; Ji-Sheng Chen
Journal:  World J Gastroenterol       Date:  2010-11-07       Impact factor: 5.742

3.  Combined hepatocellular-cholangiocarcinoma. A histologic and immunohistochemical study.

Authors:  Z D Goodman; K G Ishak; J M Langloss; I A Sesterhenn; L Rabin
Journal:  Cancer       Date:  1985-01-01       Impact factor: 6.860

4.  Histopathological classification of hepatocellular carcinoma.

Authors:  Massimo Roncalli; Young Nyun Park; Luca Di Tommaso
Journal:  Dig Liver Dis       Date:  2010-07       Impact factor: 4.088

5.  Classification of hepatocellular carcinoma according to hepatocellular and biliary differentiation markers. Clinical and biological implications.

Authors:  P C Wu; J W Fang; V K Lau; C L Lai; C K Lo; J Y Lau
Journal:  Am J Pathol       Date:  1996-10       Impact factor: 4.307

6.  Down-regulation of organic anion transporter expression in human hepatocytes exposed to the proinflammatory cytokine interleukin 1beta.

Authors:  Marc Le Vee; Philippe Gripon; Bruno Stieger; Olivier Fardel
Journal:  Drug Metab Dispos       Date:  2007-11-08       Impact factor: 3.922

7.  Underexpression of mRNA in human hepatocellular carcinoma focusing on eight loci.

Authors:  Moritoshi Kinoshita; Masahiko Miyata
Journal:  Hepatology       Date:  2002-08       Impact factor: 17.425

8.  Changes in the expression and localization of hepatocellular transporters and radixin in primary biliary cirrhosis.

Authors:  Hideyuki Kojima; Anne T Nies; Jörg König; Wolfgang Hagmann; Herbert Spring; Masahito Uemura; Hiroshi Fukui; Dietrich Keppler
Journal:  J Hepatol       Date:  2003-11       Impact factor: 25.083

9.  The human organic anion transporting polypeptide 8 (SLCO1B3) gene is transcriptionally repressed by hepatocyte nuclear factor 3beta in hepatocellular carcinoma.

Authors:  Stephan R Vavricka; Diana Jung; Michael Fried; Uwe Grützner; Peter J Meier; Gerd A Kullak-Ublick
Journal:  J Hepatol       Date:  2004-02       Impact factor: 25.083

10.  Combined hepatocellular cholangiocarcinoma originating from hepatic progenitor cells: immunohistochemical and double-fluorescence immunostaining evidence.

Authors:  F Zhang; X-P Chen; W Zhang; H-H Dong; S Xiang; W-G Zhang; B-X Zhang
Journal:  Histopathology       Date:  2008-01       Impact factor: 5.087

View more
  19 in total

Review 1.  CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects.

Authors:  Jin-Young Choi; Jeong-Min Lee; Claude B Sirlin
Journal:  Radiology       Date:  2014-09       Impact factor: 11.105

2.  Transporter Expression in Noncancerous and Cancerous Liver Tissue from Donors with Hepatocellular Carcinoma and Chronic Hepatitis C Infection Quantified by LC-MS/MS Proteomics.

Authors:  Sarah Billington; Adrian S Ray; Laurent Salphati; Guangqing Xiao; Xiaoyan Chu; W Griffith Humphreys; Mingxiang Liao; Caroline A Lee; Anita Mathias; Cornelis E C A Hop; Christopher Rowbottom; Raymond Evers; Yurong Lai; Edward J Kelly; Bhagwat Prasad; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2017-11-14       Impact factor: 3.922

3.  Correlation between Indocyanine green retention test and esophageal varices among patients with hepatocellular carcinoma.

Authors:  Andrea Lisotti; Francesco Azzaroli; Marco Montagnani; Alberto Porro; Giuseppe Mazzella
Journal:  J Gastroenterol       Date:  2014-02-08       Impact factor: 7.527

Review 4.  Organic Anion Transporting Polypeptides: Emerging Roles in Cancer Pharmacology.

Authors:  Rachael R Schulte; Richard H Ho
Journal:  Mol Pharmacol       Date:  2019-02-19       Impact factor: 4.436

Review 5.  Morphological, dynamic and functional characteristics of liver pseudolesions and benign lesions.

Authors:  Matteo Renzulli; Nicolò Brandi; Giulia Argalia; Stefano Brocchi; Andrea Farolfi; Stefano Fanti; Rita Golfieri
Journal:  Radiol Med       Date:  2022-01-13       Impact factor: 3.469

6.  Determining the efficacy of functional liver imaging score (FLIS) obtained from gadoxetic acid-enhanced MRI in patients with chronic liver disease and liver cirrhosis: the relationship between Albumin-Bilirubin (ALBI) grade and FLIS.

Authors:  Serdar Aslan; Uluhan Eryuruk; Merve Nur Tasdemir; Ismet Mirac Cakir
Journal:  Abdom Radiol (NY)       Date:  2022-06-07

Review 7.  CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features.

Authors:  Jin-Young Choi; Jeong-Min Lee; Claude B Sirlin
Journal:  Radiology       Date:  2014-10       Impact factor: 11.105

8.  Does multiparametric US improve diagnostic accuracy in the characterization of small testicular masses?

Authors:  Alfonso Reginelli; Alfredo D'Andrea; Alfredo Clemente; Andrea Izzo; Fabrizio Urraro; Fernando Scala; Valerio Nardone; Cesare Guida; Michele Scialpi; Salvatore Cappabianca
Journal:  Gland Surg       Date:  2019-09

9.  Tumor-specific expression of organic anion-transporting polypeptides: transporters as novel targets for cancer therapy.

Authors:  Veronika Buxhofer-Ausch; Lena Secky; Katrin Wlcek; Martin Svoboda; Valentinos Kounnis; Evangelos Briasoulis; Andreas G Tzakos; Walter Jaeger; Theresia Thalhammer
Journal:  J Drug Deliv       Date:  2013-02-03

10.  Evaluation of the Benefits of TACE Combined with Sorafenib for Hepatocellular Carcinoma Based on Untreatable TACE (unTACEable) Progression.

Authors:  Xinhua Zou; Wenzhe Fan; Miao Xue; Jiaping Li
Journal:  Cancer Manag Res       Date:  2021-05-18       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.